<DOC>
	<DOCNO>NCT02997280</DOCNO>
	<brief_summary>Steroid-refractory acute GVHD ( srGVHD ) one cause mortality allogeneic stem cell transplantation , steroid-refractory chronic GVHD significantly increase morbidity , aggravate quality life may also impact survival . Currently standard treatment srGVHD . One promising agent Janus kinase ( JAK ) inhibitor ruxolitinib , retrospective study demonstrate excellent response rate survival patient either acute chronic srGVHD . This study prospectively evaluate efficacy ruxolitinib srGVHD patient .</brief_summary>
	<brief_title>Ruxolitinib Steroid-refractory GVHD</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Diagnosis graftversushost disease establish base tissue biopsy Steroidrefractory acute chronic graftversushost disease accord EBMT/ELN criterion ( T. Ruutu et al , 2014 ) Age 1 70 year Karnofsky index &gt; 30 % . Ability oral drug intake Life expectancy &gt; 1 month Signed informed consent Severe organ dysfunction : AST ALT &gt; 5 upper normal limit ( exclude case relate liver GVHD ) , creatinine &gt; 2 upper normal limit Requirement vasopressor support time enrollment Uncontrolled bacterial fungal infection time enrollment Pregnancy Somatic psychiatric disorder make patient ( legal guardian ) unable sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>acute graft-versus-host disease</keyword>
	<keyword>chronic graft-versus-host disease</keyword>
	<keyword>Steroid-refractory GVHD</keyword>
	<keyword>ruxolitinib</keyword>
	<keyword>JAK inhibitor</keyword>
</DOC>